- Resverlogix’s (RVX) apabetalone treatment prevents COVID-19 in human lung cells, as per recent findings
- Researchers found apabetalone provides COVID-19 protection at comparable levels to the antiviral remdesivir
- The results are currently undergoing peer-review and are expected to be published in a scientific journal shortly
- Resverlogix is developing apabetalone, a molecule that can regulate disease-causing genes
- Resverlogix (RVX) is up 8.99 per cent and is currently trading at C$0.97 per share
Resverlogix’s (RVX) apabetalone treatment prevents COVID-19 in human lung cells, as per recent findings.
Researchers found apabetalone prevents human SARS-CoV-2 infection of human lung epithelial cells at comparable levels to the antiviral remdesivir, which is currently approved by the U.S. Food and Drug Administration as a treatment for COVID-19.
The findings provide a strong rationale for the use of apabetalone, a bromodomain and extraterminal (BET) protein inhibitor, as a therapeutic for COVID-19. Apabetalone is currently an investigational phase 3 clinical candidate with safety data in more than 4,000 subjects.
Dr. Ewelina Kulikowski, Senior Vice President, Research & Development at Resverlogix, commented,
“Our COVID-19 research program has yielded some truly extraordinary results, demonstrating apabetalone’s ability to prevent SARS-CoV-2 infection of human lung cells. Reducing cellular entry of virus particles into the lung tissue is one pillar of apabetalone’s unique dual-mechanism alongside inhibiting damaging inflammation in combatting COVID-19.”
Dr. Dalia ElGamal, co-author and Assistant Professor at the Eppley Institute for Research in Cancer and Allied Diseases at UNMC, said,
“Given apabetalone’s anti-inflammatory properties, and its favorable safety profile in human trails, I am excited to see apabetalone move forward in clinical trials for COVID-19.”
Donald McCaffrey, President and CEO of Resverlogix, added,
“This work would not have been possible without the invaluable contribution of Dr. ElGamal and colleagues at UNMC. We are grateful to work with world-class scientific leaders to characterize apabetalone as a therapeutic for COVID-19 infection for the future benefit of patients.”
Resverlogix published the results in the article, “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, which is accessible through the bioRxiv pre-print server.
The work featured in the article is currently undergoing peer-review and is expected to be published in a scientific journal shortly.
Resverlogix is developing apabetalone (RVX-208), a selective BET (bromodomain and extraterminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Resverlogix (RVX) is up 8.99 per cent and is currently trading at C$0.97 per share as of 1:15 pm ET.
